The insulin and insulin-like growth factor receptor family in neoplasia: an update

Area of Science:

• Oncology
• Endocrinology
• Molecular Biology

Background:

• Insulin-like growth factor I receptor (IGF1R) targeted therapies initially showed promise in early cancer trials.
• However, Phase III trials in unselected patient populations yielded disappointing results, necessitating a re-evaluation of treatment strategies.

Purpose of the Study:

• To explore strategies for improving the efficacy of IGF1R-targeted cancer therapies.
• To investigate the role of predictive biomarkers, combination therapies, and alternative targeting approaches.
• To contextualize IGF1R signaling within the broader pathophysiology linking metabolic diseases to cancer.

Main Methods:

• Review of early and Phase III clinical trial data for IGF1R-specific antibodies.
• Analysis of potential predictive biomarkers for patient stratification.
• Evaluation of alternative therapeutic strategies including ligand-specific antibodies and tyrosine kinase inhibitors.
• Consideration of the interplay between insulin/IGF signaling, metabolic diseases (obesity, diabetes), and cancer.

Main Results:

• Phase III trials of IGF1R antibodies in unselected patients have not met expectations.
• Predictive biomarkers are crucial for identifying likely responders to IGF1R-targeted therapies.
• Alternative strategies like ligand-specific antibodies and receptor tyrosine kinase inhibitors warrant further investigation.
• The insulin/IGF signaling pathway is implicated in the link between metabolic dysfunction and cancer development.

Conclusions:

• Future clinical studies targeting IGF1R should incorporate predictive biomarkers and explore rational combination therapies.
• Alternative strategies, including targeting ligands or using receptor tyrosine kinase inhibitors, may offer improved outcomes.
• Understanding the broader context of insulin and IGF signaling in metabolic diseases and cancer is essential for developing effective treatments.
• The IGF1 receptor family is a key consideration in the development of PI3K-AKT pathway inhibitors for cancer therapy.